Limited efficacy of APRIL CAR in patients with multiple myeloma indicate challenges in the use of natural ligands for CAR T-cell therapy

BACKGROUND: We used a proliferating ligand (APRIL) to construct a ligand-based third generation chimeric antigen receptor (CAR) able to target two myeloma antigens, B-cell maturation antigen (BCMA) and transmembrane activator and CAML interactor. METHODS: The APRIL CAR was evaluated in a Phase 1 cli...

Descripción completa

Detalles Bibliográficos
Autores principales: Lee, Lydia, Lim, Wen Chean, Galas-Filipowicz, Daria, Fung, Kent, Taylor, Julia, Patel, Dominic, Akbar, Zulaikha, Alvarez Mediavilla, Elena, Wawrzyniecka, Patrycja, Shome, Debarati, Reijmers, Rogier M, Gregg, Trillian, Wood, Leigh, Day, William, Cerec, Virginie, Ferrari, Mathieu, Thomas, Simon, Cordoba, Shaun, Onuoha, Shimobi, Khokhar, Nushmia, Peddareddigari, Vijay, Al-Hajj, Muhammad, Cavet, Jim, Zweegman, Sonja, Rodriguez-Justo, Manuel, Yong, Kwee, Pule, Martin, Popat, Rakesh
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BMJ Publishing Group 2023
Materias:
Immune Cell Therapies and Immune Cell Engineering
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10314698/
https://www.ncbi.nlm.nih.gov/pubmed/37399355
http://dx.doi.org/10.1136/jitc-2023-006699

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10314698/
https://www.ncbi.nlm.nih.gov/pubmed/37399355
http://dx.doi.org/10.1136/jitc-2023-006699

Ejemplares similares